Rice University and Houston Methodist have partnered to create the Digital Health Institute, combining advanced technology, artificial intelligence, and interdisciplinary expertise to transform health care. Photos courtesy

Rice University and Houston Methodist have established through a multi-year joint effort the Digital Health Institute, which aims to transform healthcare through advanced technology and the collaborative expertises of the university and hospital.

Rice’s leadership in engineering, digital health and artificial intelligence will combine with Houston Methodist’s academic medicine and research infrastructure.

“This partnership embodies Rice’s bold vision to lead at the forefront of innovation in health and responsible AI,” Rice President Reginald DesRoches says in a news release. “By combining our strengths with Houston Methodist, we are creating a transformative platform to address critical challenges in healthcare with solutions that are ethical, accessible and impactful. This initiative exemplifies our commitment to driving interdisciplinary collaboration and advancing global health for the benefit of humanity.”

Leading the initiative will be Rice’s Ashutosh Sabharwal, the Ernest Dell Butcher Professor of Engineering and professor of electrical and computer engineering, and Houston Methodist’s Dr. Khurram Nasir, the Centennial Chair in Cardiovascular Medicine, and Dr. William Zoghbi, division chief of cardiovascular prevention and wellness. Rice and Houston Methodist have worked previously with the Center for Neural Systems Restoration that opened earlier this year and the Center for Human Performance that was established in 2022.

The Digital Health Institute allows for both institutions to share data, and resources that focus on key areas like the early detection through AI algorithms for early diagnosis of cancer, infections, cardiovascular diseases and other conditions, predictive analytics that utilize real-time monitoring that can predict and prevent events such as strokes and heart failure, and the development of novel sensors, wearables and ingestibles to innovate new remote monitoring and care pathways.

The Digital Health Institute will also work to utilize more personalized medicine efforts, developments of new novel and assistive technologies, expansion of telemedicine, and proactive self-care management through AI-driven patient self-management.

“This partnership between our institutions marks a bold new chapter in driving meaningful innovation at the intersection of healthcare and technology through solutions that are both visionary and practical,” Dr. Marc Boom, president and CEO of Houston Methodist, adds. “Our long-standing relationship with Rice University has produced impactful collaborations, but this initiative is by far the most transformative endeavor in our shared commitment of leading medicine through innovation.”

Rice President Reginald DesRoches and Houston Methodist CEO Marc Boom announced the new partnership at the Ion. Photo courtesy of Rice

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”